Cargando…
Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that ca...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366795/ https://www.ncbi.nlm.nih.gov/pubmed/34401879 http://dx.doi.org/10.1101/2021.08.06.455494 |
_version_ | 1783738952912470016 |
---|---|
author | Lo, Michael K. Shrivastava-Ranjan, Punya Chatterjee, Payel Flint, Mike Beadle, James R. Valiaeva, Nadejda Schooley, Robert T. Hostetler, Karl Y. Montgomery, Joel M. Spiropoulou, Christina |
author_facet | Lo, Michael K. Shrivastava-Ranjan, Punya Chatterjee, Payel Flint, Mike Beadle, James R. Valiaeva, Nadejda Schooley, Robert T. Hostetler, Karl Y. Montgomery, Joel M. Spiropoulou, Christina |
author_sort | Lo, Michael K. |
collection | PubMed |
description | The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo. |
format | Online Article Text |
id | pubmed-8366795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-83667952021-08-17 Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) Lo, Michael K. Shrivastava-Ranjan, Punya Chatterjee, Payel Flint, Mike Beadle, James R. Valiaeva, Nadejda Schooley, Robert T. Hostetler, Karl Y. Montgomery, Joel M. Spiropoulou, Christina bioRxiv Article The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo. Cold Spring Harbor Laboratory 2021-08-10 /pmc/articles/PMC8366795/ /pubmed/34401879 http://dx.doi.org/10.1101/2021.08.06.455494 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) . |
spellingShingle | Article Lo, Michael K. Shrivastava-Ranjan, Punya Chatterjee, Payel Flint, Mike Beadle, James R. Valiaeva, Nadejda Schooley, Robert T. Hostetler, Karl Y. Montgomery, Joel M. Spiropoulou, Christina Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) |
title | Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) |
title_full | Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) |
title_fullStr | Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) |
title_full_unstemmed | Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) |
title_short | Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) |
title_sort | broad-spectrum in vitro antiviral activity of odbg-p-rvn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (gs-441524) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366795/ https://www.ncbi.nlm.nih.gov/pubmed/34401879 http://dx.doi.org/10.1101/2021.08.06.455494 |
work_keys_str_mv | AT lomichaelk broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT shrivastavaranjanpunya broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT chatterjeepayel broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT flintmike broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT beadlejamesr broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT valiaevanadejda broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT schooleyrobertt broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT hostetlerkarly broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT montgomeryjoelm broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 AT spiropoulouchristina broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524 |